Monitor for any pattern of increasing insider selling in coming weeks; currently, this level of activity is within normal range for executives managing personal holdings.
XNCR drugs
XNCR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $11.16entry
- T+1 · 9mo ago +1.43%α +2.75% · $11.32
- T+5 · 8mo ago +4.03%α +6.27% · $11.61
- T+20 · 8mo ago +14.78%α +18.57% · $12.81
- T+60 · 6mo ago +5.73%α −5.57% · $11.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Five open-market share sales by three Xencor executives, CEO, CFO, and General Counsel, over two days, totaling $324,274. The transactions are small relative to the company's $830M market cap, representing just 0.04% of equity value, and appear routine.
Key Financial Metrics
Key Facts
- CEO Dahiyat Bassil sold 21,476 shares for $240,017 across two trades on March 5 and 6.
- CFO Bart Jan Cornelissen sold 2,517 shares for $28,305 on March 5.
- General Counsel Celia Eckert sold 5,011 shares for $55,952 across two trades.
- All transactions were open-market sales (Form 4 code 'S') with no non-cash or derivative-related activity.
- Total insider selling cluster value: $324,274 over 7 days, or 0.04% of $830M market cap.
Financial Impact
$324,274 in total open-market sales by insiders
Risk Factors
- Perception risk if selling continues or accelerates ahead of next earnings or clinical catalysts.
- Concentration of sales among top executives (CEO, CFO, GC) may raise questions, though dollar amounts are small.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (5 trades, 7d window) | cluster-XNCR-1773086823812 |
Track record
20 reports on XNCR
4 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +67.24% at T+60 after the May 5, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $35.40 Now $35.40 +0.00% settles Nov 18
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $39.23 Now $35.40 −9.77% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Neutral 4/10 Entry $37.09 to $35.40 Now $35.40 −4.56% ▼ −4.56% −2.65% vs SPY
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $38.13 to $37.09 Now $35.40 −7.16% ▼ −2.73% −2.36% vs SPY
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $39.97 to $38.13 Now $35.40 −11.43% ▼ −4.60% −4.25% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $35.75 to $38.59 Now $35.40 −0.98% ▲ +7.94% +5.58% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $34.05 to $35.75 Now $35.40 +3.96% ▲ +4.99% +4.68% vs SPY
- Oct 30, 202617d ago SC 13G/A Bearish 4/10 Entry $29.82 to $29.66 Now $35.40 −18.71% ▲ +0.54% +0.06% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $29.99 to $29.21 Now $35.40 +18.04% ▼ −2.60% −2.22% vs SPY
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $29.18 to $29.99 Now $35.40 +21.32% ▲ +2.78% +2.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers